PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
June 1, 2024Journal of Clinical Oncology

A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.

View Full Paper
Ask AI
Bookmark
Share

Authors

EGElena GarraldaJWJudy S. WangAGAndrew G. Gianoukakis

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Garralda et al. (2024) studied this question.

synapsesocial.com/papers/68e66c5ab6db6435875f746bhttps://doi.org/10.1200/jco.2024.42.16_suppl.8556
View Full Paper
Ask AI
Bookmark
Share